Author/Authors :
Sousa Pinheiro, Lucio Henrique Department of Pharmacy - Laboratory of Hematology - Federal University of Sergipe, São Cristóvão, Brazil , Trindade, Louise Dantas Department of Pharmacy - Laboratory of Hematology - Federal University of Sergipe, São Cristóvão, Brazil , Oliveira Costa, Amanda Fernandes de Department of Medicine - University of São Paulo, São Paulo, Brazil , Lima Silva, Nathanielly de Department of Pharmacy - Laboratory of Hematology - Federal University of Sergipe, São Cristóvão, Brazil , Sandes, Alex Freire Department of Medicine - Hematology Course - Federal University of São Paulo, Brazil , Prado Nunes, Marco Antônio Department of Medicine - Federal University of Sergipe, Sergipe, Brazil , Correa, Cristiane Bani Department of Morphology - Federal University of Sergipe, São Cristóvão, Brazil , Cardoso Almeida, Carlos Arthur Nursing and Pharmacy School - Federal University of Alagoas, Maceió, Brazil , Silveira da Cruz, Geydson University Hospital - Federal University of Sergipe, Aracaju, Brazil , Lyra Junior, Divaldo Pereira de Department of Pharmacy - Laboratory of Hematology - Federal University of Sergipe, São Cristóvão, Brazil , Schimieguel, Dulce Marta Department of Pharmacy - Laboratory of Hematology - Federal University of Sergipe, São Cristóvão, Brazil
Abstract :
Background: The aim of this review was to evaluate the influence of aberrant phenotypes in prognosis and survival in acute myeloid leukemia (AML) patients by multiparametric flow cytometry.
Materials and Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a review of PubMed, Scopus, Science Direct and Web of Science was carried out through 1998 to 2016, conducted by two reviewers independently, evaluating titles, abstracts and full-texts of the selected studies.
Results: Ten studies were included on this review, in which the aberrant phenotype expression of 17 markers were detected in AML patients. From these, 11 aberrant phenotypes were associated with prognosis, which eight had shown negative impact on prognosis: CD7, CD56, CD15, CD2, CD3, CD90low, CD123high, CD117high, and three others were associated with good prognosis: CD19, CD98high and CD117+/CD15+. Meta-analysis showed that aberrant expression of CD56 as a poor prognostic marker with unfavorable outcomes is implicated in decreased overall survival in AML patients in 28 months (95% CI: 0.62 to 0.92).
Conclusion: This was observed when there was association between CD56 expression and other prognostic factors, influencing on patients’ management care and treatment.
Keywords :
Aberrant phenotype , Acute myeloid leukemia , Immunophenotyping , Prognosis , Survival
